JP2022552009A5 - - Google Patents
Info
- Publication number
- JP2022552009A5 JP2022552009A5 JP2022523031A JP2022523031A JP2022552009A5 JP 2022552009 A5 JP2022552009 A5 JP 2022552009A5 JP 2022523031 A JP2022523031 A JP 2022523031A JP 2022523031 A JP2022523031 A JP 2022523031A JP 2022552009 A5 JP2022552009 A5 JP 2022552009A5
- Authority
- JP
- Japan
- Prior art keywords
- lnp
- substituted
- composition
- group
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025185622A JP2026012402A (ja) | 2019-10-18 | 2025-11-04 | 薬物送達のための脂質及び脂質ナノ粒子製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923258P | 2019-10-18 | 2019-10-18 | |
| US62/923,258 | 2019-10-18 | ||
| PCT/US2020/056252 WO2021077066A1 (en) | 2019-10-18 | 2020-10-19 | Lipid and lipid nanoparticle formulation for drug delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025185622A Division JP2026012402A (ja) | 2019-10-18 | 2025-11-04 | 薬物送達のための脂質及び脂質ナノ粒子製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022552009A JP2022552009A (ja) | 2022-12-14 |
| JP2022552009A5 true JP2022552009A5 (enExample) | 2023-10-23 |
Family
ID=75538682
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523031A Pending JP2022552009A (ja) | 2019-10-18 | 2020-10-19 | 薬物送達のための脂質及び脂質ナノ粒子製剤 |
| JP2025185622A Pending JP2026012402A (ja) | 2019-10-18 | 2025-11-04 | 薬物送達のための脂質及び脂質ナノ粒子製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025185622A Pending JP2026012402A (ja) | 2019-10-18 | 2025-11-04 | 薬物送達のための脂質及び脂質ナノ粒子製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220396556A1 (enExample) |
| EP (1) | EP4045020A4 (enExample) |
| JP (2) | JP2022552009A (enExample) |
| KR (1) | KR20220084365A (enExample) |
| CN (1) | CN114828836A (enExample) |
| CA (1) | CA3155074A1 (enExample) |
| WO (1) | WO2021077066A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022115645A1 (en) | 2020-11-25 | 2022-06-02 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| CN113785975B (zh) * | 2021-09-09 | 2023-08-29 | 天津医科大学 | 精胺、亚精胺脂质体在抗氧化、抗衰老中的应用 |
| AR128959A1 (es) * | 2022-04-04 | 2024-06-26 | Spark Therapeutics Inc | Mejora inmunológica del tratamiento del cáncer |
| CN119325466A (zh) * | 2022-04-08 | 2025-01-17 | 尚威天成信使核糖核酸治疗公司 | 可电离脂质化合物和脂质纳米颗粒组合物 |
| CA3256897A1 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for the administration of nucleic acids and their methods of use |
| CN117264955A (zh) * | 2022-09-23 | 2023-12-22 | 北京键凯科技股份有限公司 | 一种抑制top1基因表达的干扰rna及其应用 |
| WO2024183821A1 (zh) * | 2023-03-09 | 2024-09-12 | 上海吉量医药工程有限公司 | 可离子化脂质分子及其制备方法和应用 |
| CN116082184B (zh) * | 2023-04-12 | 2023-06-30 | 山东大学 | 基于环己二胺的可电离脂质、脂质纳米颗粒及其制备方法与应用 |
| WO2025038494A1 (en) | 2023-08-11 | 2025-02-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation |
| WO2025059112A1 (en) * | 2023-09-11 | 2025-03-20 | The Trustees Of The University Of Pennsylvania | Compositions and methods for t cell targeted extrahepatic delivery of therapeutic agents |
| CN117482066B (zh) * | 2023-11-02 | 2024-08-13 | 深圳市易瑞生物技术股份有限公司 | 脂质组合物和用于脂质组合物的化合物 |
| CN121241044A (zh) * | 2024-04-01 | 2025-12-30 | 深圳厚存纳米药业有限公司 | 脂质和脂质纳米颗粒制剂 |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2740000C (en) * | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| EP3269395A1 (en) * | 2008-11-07 | 2018-01-17 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| US7635707B1 (en) * | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| JP6620093B2 (ja) * | 2013-07-23 | 2019-12-11 | アービュートゥス バイオファーマ コーポレイションＡｒｂｕｔｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐｏｒａｔｉｏｎ | メッセンジャーｒｎａを送達するための組成物及び方法 |
| US20190274968A1 (en) * | 2016-10-27 | 2019-09-12 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
-
2020
- 2020-10-19 KR KR1020227016630A patent/KR20220084365A/ko not_active Ceased
- 2020-10-19 JP JP2022523031A patent/JP2022552009A/ja active Pending
- 2020-10-19 WO PCT/US2020/056252 patent/WO2021077066A1/en not_active Ceased
- 2020-10-19 CN CN202080088019.XA patent/CN114828836A/zh active Pending
- 2020-10-19 EP EP20877084.2A patent/EP4045020A4/en active Pending
- 2020-10-19 CA CA3155074A patent/CA3155074A1/en active Pending
- 2020-10-19 US US17/769,858 patent/US20220396556A1/en active Pending
-
2025
- 2025-11-04 JP JP2025185622A patent/JP2026012402A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022552008A5 (enExample) | ||
| JP2022552009A5 (enExample) | ||
| JP2025175052A5 (enExample) | ||
| JP2026012402A5 (enExample) | ||
| AU2019345104B2 (en) | Therapeutic nanoparticles and methods of use thereof | |
| JP2021535227A5 (enExample) | ||
| US10626393B2 (en) | Delivering CRISPR therapeutics with lipid nanoparticles | |
| Dass | Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection | |
| US20180245074A1 (en) | Treating hepatitis b virus infection using crispr | |
| US20210330600A1 (en) | Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same | |
| JP2024518375A5 (enExample) | ||
| JP2012509366A (ja) | 核酸送達系のための放出可能ポリマー脂質 | |
| JP2011529912A (ja) | 核酸送達システム用のナノ粒子組成物 | |
| US20240115730A1 (en) | Tissue-specific nucleic acid delivery by 1,2-dioleoyl-3-trimethylammonium-propane (dotap) lipid nanoparticles | |
| JP2024540108A5 (enExample) | ||
| US20250041325A1 (en) | Lipid-based compositions and methods thereof | |
| JP2021526505A (ja) | 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法 | |
| Lee et al. | Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor | |
| JP2025541727A (ja) | 新規のポリグリセロールコンジュゲート脂質及びそれを含む脂質ナノ粒子組成物 | |
| CN110022895A (zh) | 用于治疗乙型肝炎的治疗组合物和方法 | |
| CA3262393A1 (en) | Lipid composition targeting antigen-presenting cells, and related uses | |
| JP2003522193A5 (enExample) | ||
| EP4387657A1 (en) | Lipid nanoparticle formulations | |
| JPWO2022244815A5 (enExample) | ||
| JP5299424B2 (ja) | 薬物担体 |